Effectiveness of age-based strategies to increase influenza vaccination coverage among high risk subjects in Madrid (Spain)

Research highlights ► The probability of a subject aged 60–64 living in Madrid of being vaccinated was almost two times higher (OR 1.95 CI 95% 1.46–2.61) than a person of the same age who lived in a region of Spain where the universal recommendation for influenza vaccine started at 65 years. ► Lower...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2011-04, Vol.29 (16), p.2840-2845
Main Authors: Jiménez-García, Rodrigo, Rodríguez-Rieiro, Cristina, Hernández-Barrera, Valentín, Andres, Ana Lopez de, Cuadrado, Agustin Rivero, Laso, Angel Rodriguez, Carrasco-Garrido, Pilar
Format: Article
Language:English
Subjects:
Adherence
Adolescent
Adult
Age
Age Distribution
Aged
Allergy and Immunology
Applied microbiology
Asthma
Biological and medical sciences
Bronchitis
Cardiovascular disease
Chronic illnesses
Coverage
Diabetes
Embolisms
Female
Fundamental and applied biological sciences. Psychology
Heart attacks
Humans
Immunization
Influenza
Influenza Vaccines - administration & dosage
Influenza, Human - epidemiology
Influenza, Human - prevention & control
Logistic Models
Male
Microbiology
Middle Aged
Mortality
Multivariate Analysis
risk
Spain - epidemiology
Strategies
surveys
vaccination
Vaccination - statistics & numerical data
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Variables
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Research highlights ► The probability of a subject aged 60–64 living in Madrid of being vaccinated was almost two times higher (OR 1.95 CI 95% 1.46–2.61) than a person of the same age who lived in a region of Spain where the universal recommendation for influenza vaccine started at 65 years. ► Lowering the age for universal influenza vaccination should be considered as a strategy to increase coverages among high risk patients who suffer from chronic underlying conditions.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.02.004